Chen Cong, Ge Jing, Lu Qibin, Ping Guoqiang, Yang Chunqing, Fang Xuefeng
Department of Gynecology of Traditional Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, 210029, China.
Department of Endocrinology, Jiangsu Provincial Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu Province, 210029, China.
J Ovarian Res. 2015 May 9;8:28. doi: 10.1186/s13048-015-0155-1.
Lysine-specific demethylase 1(LSD1) is implicated in the tumorigenesis and progression in various cancers. However, the expression of LSD1 in epithelial ovarian cancer and its clinical significance has not been examined in detail.
Immunohistochemical was used to detect the expression of LSD1 in normal ovarian epithelial tissues, cystadenoma, borderline cystadenoma, and cystadenocarcinoma. Next, the correlations between expression of LSD1 and clinicopathological features was assessed in 96 species of serous cystadenocarcinoma and 36 species of mucinous cystadenocarcinoma.
Immunohistochemical results showed that the expression of LSD1 was gradually increased from benign cystadenoma and borderline cystadenoma to cystadenocarcinoma. The positive ratio of LSD1 expression was 50% in normal ovarian epithelial tissues, 72% in serous cystadenoma, 73% in mucinous cystadenoma, 82% in borderline serous cystadenoma, 83% in borderline mucinous cystadenoma, 94% in serous cystadenocarcinoma and 92% in mucinous cystadenocarcinoma, respectively. LSD1 expression levels were associated with International Federation of Gynecology and Obstetrics stage and lymphatic metastasis in both serous and mucinous cystadenocarcinoma samples. Kaplan-Meier curves suggested that overall survival time of patients with high LSD1 expression was significantly shorter than that of patients with low LSD1 expression. Multivariate Cox proportional hazard regression indicated that higher LSD1 expression was a significant independent predictor of poor survival of EOC patients (P = 0.016).
These results suggest that LSD1 may be involved in carcinogenesis and progression with promising therapeutic potential for epithelial ovarian cancer.
赖氨酸特异性去甲基化酶1（LSD1）与多种癌症的肿瘤发生和进展有关。然而，LSD1在上皮性卵巢癌中的表达及其临床意义尚未得到详细研究。
采用免疫组织化学法检测LSD1在正常卵巢上皮组织、囊腺瘤、交界性囊腺瘤和囊腺癌中的表达。接下来，评估96例浆液性囊腺癌和36例黏液性囊腺癌中LSD1表达与临床病理特征之间的相关性。
免疫组织化学结果显示，从良性囊腺瘤、交界性囊腺瘤到囊腺癌，LSD1的表达逐渐增加。LSD1表达的阳性率在正常卵巢上皮组织中为50%，浆液性囊腺瘤中为72%，黏液性囊腺瘤中为73%，交界性浆液性囊腺瘤中为82%，交界性黏液性囊腺瘤中为83%，浆液性囊腺癌中为94%，黏液性囊腺癌中为92%。在浆液性和黏液性囊腺癌样本中，LSD1表达水平与国际妇产科联盟分期和淋巴转移相关。Kaplan-Meier曲线表明，LSD1高表达患者的总生存时间明显短于LSD1低表达患者。多因素Cox比例风险回归表明，较高的LSD1表达是上皮性卵巢癌患者生存不良的显著独立预测因素（P = 0.016）。
这些结果表明，LSD1可能参与上皮性卵巢癌的致癌过程和进展，具有潜在的治疗潜力。
